文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

吸入一氧化氮在COVID-19相关急性呼吸窘迫综合征患者中的应用:治疗方式、临床反应与结局

Inhaled nitric oxide in patients with acute respiratory distress syndrome caused by COVID-19: treatment modalities, clinical response, and outcomes.
PubMed 文献 · Ann Intensive Care · 2023-06-27
一句话结论多中心回顾性队列显示,C-ARDS患者吸入NO后6小时45.7%有氧合反应,ECMO候选者中51.6%经iNO后不再符合ECMO标准且死亡率更低(校正OR 0.23)。

该多中心回顾性队列研究纳入法国2020年2月底至12月的300例COVID-19相关ARDS患者,描述吸入一氧化氮(iNO)的使用方式、临床反应和结局。所有患者均接受保护性通气,68%在iNO前已俯卧位;iNO启动时61%为重度ARDS,中位剂量10 ppm,中位疗程2.8天。6小时时45.7%患者PaO2/FiO2改善≥20%(反应者),ARDS严重程度是唯一预测因素;总体死亡率在反应者与非反应者间无显著差异。在62例iNO前符合ECMO标准的难治性ARDS患者中,32例(51.6%)6小时后不再符合ECMO标准,其死亡率显著低于仍符合者(校正OR 0.23,95%CI 0.06-0.89,p=0.03)。作者认为iNO可改善C-ARDS患者氧合,尤其在重症患者中,但需前瞻性研究证实。

要点

  • 在C-ARDS患者中,iNO启动后6小时45.7%的患者PaO2/FiO2改善≥20%(反应者),ARDS严重程度是唯一预测反应的因素。
  • iNO前符合ECMO标准的62例难治性ARDS患者中,32例(51.6%)经iNO 6小时后不再符合ECMO标准,其死亡率显著低于仍符合者(校正OR 0.23,95%CI 0.06-0.89,p=0.03)。
  • 总体可评估患者中,6小时反应者与非反应者的粗死亡率无显著差异。
  • iNO中位启动剂量为10(7-13)ppm,中位疗程2.8(1.1-5.5)天;启动时61%为重度ARDS、37%为中度、2%为轻度。
  • 所有患者均接受保护性通气,68%在iNO启动前已行俯卧位通气。

适用人群与场景

  • 法国多中心收治的COVID-19相关ARDS成人患者,2020年2月底至12月纳入,共300例(女性22.3%),84.5%超重,69.0%至少有一种合并症。
  • ICU入院时中位年龄66(57-72)岁,SAPS II 37(29-48),SOFA评分5(3-8)。
  • 所有患者均接受保护性通气策略,68%在iNO启动前已行俯卧位通气。

诊断标准与关键阈值

  • iNO启动时ARDS严重程度:轻度2%、中度37%、重度61%。
  • iNO反应者定义为启动后6小时PaO2/FiO2较基线改善≥20%。
  • 难治性ARDS定义:iNO启动前符合ECMO标准。

处置流程与药物剂量

  • 吸入一氧化氮(iNO)启动中位剂量为10(7-13)ppm,中位治疗时长2.8(1.1-5.5)天。
  • 所有患者均接受保护性通气策略。
  • 68%的患者在iNO启动前已行俯卧位通气。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入300例C-ARDS患者,2020年2月底至12月在法国进行。
  • iNO启动后6小时,45.7%的患者PaO2/FiO2改善≥20%(反应者);ARDS严重程度是唯一与iNO反应相关的预测因素。
  • 在所有可评估患者中,6小时反应者与非反应者的粗死亡率无显著差异。
  • 62例iNO前符合ECMO标准的难治性ARDS患者中,32例(51.6%)在iNO 6小时后不再符合ECMO标准;后者死亡率显著低于仍符合ECMO标准者,校正OR 0.23(95%CI 0.06-0.89,p=0.03)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,iNO可改善C-ARDS患者的动脉氧合,这种改善似乎在病情最严重的患者中更为明显。
  • 作者认为,在符合ECMO标准的患者中,iNO驱动的气体交换改善与更好的生存相关。
  • 作者指出,这些结果必须在设计良好的前瞻性研究中证实。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Inhaled nitric oxide (iNO) has been widely used in patients with COVID-19-related acute respiratory distress syndrome (C-ARDS), though its physiological effects and outcome are debated in this setting. The objective of this cohort study was to describe the modalities of iNO use, clinical response, and outcomes in a large cohort of C-ARDS patients.

METHODS: Multicentre, retrospective cohort study conducted in France.

RESULTS: From end February to December 2020, 300 patients (22.3% female) were included, 84.5% were overweight and 69.0% had at least one comorbidity. At ICU admission, their median (IQR) age, SAPS II, and SOFA score were 66 (57-72) years, 37 (29-48), and 5 (3-8), respectively. Patients were all ventilated according to a protective ventilation strategy, and 68% were prone positioned before iNO initiation. At iNO initiation, 2%, 37%, and 61% of patients had mild, moderate, and severe ARDS, respectively. The median duration of iNO treatment was 2.8 (1.1-5.5) days with a median dosage of 10 (7-13) ppm at initiation. Responders (PaO2/FiO2 ratio improving by 20% or more) represented 45.7% of patients at 6 h from iNO initiation. The severity of ARDS was the only predictive factor associated with iNO response. Among all evaluable patients, the crude mortality was not significantly different between responders at 6 h and their counterparts. Of the 62 patients with refractory ARDS (who fulfilled extracorporeal membrane oxygenation criteria before iNO initiation), 32 (51.6%) no longer fulfilled these criteria after 6 h of iNO. The latter showed significantly lower mortality than the other half (who remained ECMO eligible), including after confounder adjustment (adjusted OR: 0.23, 95% CI 0.06, 0.89, p = 0.03).

CONCLUSIONS: Our study reports the benefits of iNO in improving arterial oxygenation in C-ARDS patients. This improvement seems more relevant in the most severe cases. In patients with ECMO criteria, an iNO-driven improvement in gas exchange was associated with better survival. These results must be confirmed in well-designed prospective studies.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Mekontso Dessap A, Papazian L, Schaller M, et al. Inhaled nitric oxide in patients with acute respiratory distress syndrome caused by COVID-19: treatment modalities, clinical response, and outcomes. Ann Intensive Care. 2023. PMID: 37368036. doi:10.1186/s13613-023-01150-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。